Centre for Oncology and Immunology
Derek Lee is an accomplished researcher with extensive experience in oncology and cancer biology. Currently serving as an Honorary Senior Research Associate at the Centre for Oncology and Immunology since September 2021, Derek is involved in cancer biomarker discovery and anti-cancer drug development for liver cancer, while also supervising junior staff and optimizing laboratory standards. As a Post-doctoral Fellow at The University of Hong Kong since March 2020, Derek leads experimental projects focused on metabolic reprogramming in hepatocellular carcinoma and has contributed to interdisciplinary research on treatment resistance in cholangiocarcinoma. Derek has published in high-quality peer-reviewed journals and successfully secured funding for research projects. Previous experience includes a role as a Research Assistant in the Division of Neurosurgery at HKUMed, where Derek contributed to studies on chemoresistance in glioblastoma. Academic credentials include a PhD and a Master’s degree in Oncology and Cancer Biology from The University of Hong Kong, as well as a Bachelor’s degree in Human Biology from the University of Toronto.
This person is not in any teams
This person is not in any offices
Centre for Oncology and Immunology
Centre for Oncology and Immunology aims to harness the power of biotechnology to develop innovative therapies to combat these hard-to-treat malignancies and bring hope to millions of cancer patients around the world. The Centre’s research team comprises globally renowned researchers who bring with them a wealth of complementary expertise and experience in oncology research, technology adoption, and commercialization. Individually, their research programs have led to major breakthroughs, including the devising of immunotherapy and checkpoint inhibition strategies that have been adopted as anti-cancer treatments, the establishment of next-generation organoid-based cell models for precision oncology, and the development of a diagnostic test for Lynch Syndrome (hereditary colon cancer). The Centre will employ novel functional screens as well as genomic and proteomic techniques to identify novel “druggable” cancer targets. Leveraging the translational and clinical trial expertise of its lead scientists, the Centre will establish a number of advanced technical platforms to facilitate its overall goal of bringing candidate drugs and novel immunotherapy approaches into clinics.